Shopping Cart 0
Cart Subtotal
AED 0

Physician Perspectives 2017: Use of ustekinumab in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

Physician Perspectives 2017: Use of ustekinumab in IBD

Summary

This Physician Perspectives survey focuses on the use of ustekinumab in IBD.

UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn's disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.

73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.

Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.

The report includes following topics-

- Current clinical use of UST

- UST safety & efficacy

- UST patient monitoring

- Treatment response to UST

- UST treatment strategies

- Future use in UC.

Scope

- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists

- Physicians interviewed were from 5EU and US countries

- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

- Qualitative insight from 100 high-prescribing specialists in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of contents

Executive Summary

Methodology

Survey Results

Demographics

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ustekinumab, Crohn's disease, ulcerative colitis


Companies

Janssen

Takeda

AbbVie

Company Profile

Company Profile Title

Physician Perspectives 2017: Use of ustekinumab in IBD

Summary

This Physician Perspectives survey focuses on the use of ustekinumab in IBD.

UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn's disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.

73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.

Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.

The report includes following topics-

- Current clinical use of UST

- UST safety & efficacy

- UST patient monitoring

- Treatment response to UST

- UST treatment strategies

- Future use in UC.

Scope

- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists

- Physicians interviewed were from 5EU and US countries

- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

- Qualitative insight from 100 high-prescribing specialists in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of contents

Executive Summary

Methodology

Survey Results

Demographics

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ustekinumab, Crohn's disease, ulcerative colitis


Companies

Janssen

Takeda

AbbVie